GLP-1 receptor agonists such as semaglutide and tirzepatide are FDA-regulated for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. Las Vegas runs around the clock, and dealers, servers, performers and resort staff working overnight and rotating shifts rarely fit a daytime clinic into their week - even as the job keeps appearance and stamina front of mind. Telehealth works on their clock: a licensed Nevada physician reviews your online assessment under Nevada Revised Statutes §629.515, and compounded medication from an FDA-registered 503B pharmacy ships to your Las Vegas address. Monthly cost runs $199–$379 versus about $1,247 for brand-name Ozempic or Wegovy. Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Serving Las Vegas ZIP codes: 89101, 89102, 89104, 89109, 89119.
Local clinics serving North Last Vegas, North Las Vegas: Medi-Slim Weight Loss & Spa, Kohn Medical & Weight Loss: Ronald Kohn, MD and Clinica Mi Pueblo - Las Vegas #2842. Many patients compare these in-person options against licensed GLP-1 telehealth — prescribed online, shipped to the door.
Weight-Loss Injections seen from North Last Vegas, North Las Vegas, without the jargon. The right starting point is not the brand but the molecule: understanding GLP-1 vs dual agonist shapes the rest of the decision.
Certain histories (pancreatitis, some familial thyroid cancers) point toward other options: hence the importance of the medical questionnaire. The goal of the evaluation is not to screen for the sake of screening, but to make sure the expected benefit outweighs the risks.
Around North Last Vegas, North Las Vegas in Clark County, 3 weight-management practice(s) are listed locally. In this state, Nevada Revised Statutes §629.515; the reference body is Nevada State Board of Medical Examiners. Weight-Loss Injections belongs to the 'Category: injectable GLP-1 and dual-agonist treatments' class and is given as a weekly subcutaneous injections, most often at home. Associated brands include Wegovy, Zepbound, Ozempic, Mounjaro.
The two main ones are semaglutide (GLP-1) and tirzepatide (dual GIP/GLP-1). Tirzepatide shows higher average loss in trials, but the choice depends on tolerance and cost.
The approved molecules (semaglutide, tirzepatide) have a documented safety profile under medical supervision; they require a prescription and monitoring.
Often a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, but only the medical evaluation decides.
Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Licensed in Nevada. All prescriptions issued under Nevada Revised Statutes §629.515 and supervised by Nevada State Board of Medical Examiners.